Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
Active, not recruiting · NCT03529422 · Registry updated 2026-06-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Site, Stomatognathic Diseases, laryngeal disorder, lymphoid interstitial pneumonia, mouth disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-06-23 | NCT03529422 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| UNC Lineberger Comprehensive Cancer Center | 125 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Medical University of South Carolina - Hollings Cancer Center | Charleston | United States | 5 |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 243 |
| University of Alabama at Birmingham | Birmingham | United States | 247 |